US Food and Drug Administration Commissioner Robert Califf met virtually on 12 January with the Endocrine Society to discuss the current research around puberty-delaying medicines, another signal that the FDA may soon need to weigh in on a contentious topic surrounding off-label use that is leading to uneven access to medical care for children and teenagers around the country.
The agency must eventually respond to a recent citizen petition that wants FDA to help build out the scientific evidence on the use of puberty blockers in children with gender...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?